Sanjiv Patel, the President and CEO of Relay Therapeutics, Inc., has sold 48,199 shares of common stock, as reported in a recent SEC filing. This transaction is significant as it reflects the ongoing management of stock holdings by corporate executives in the biotechnology sector.
The sale took place on October 7, 2026, at a weighted average price of $18.10 per share. Following this transaction, Patel retains ownership of 471,301 shares directly, alongside additional shares held in irrevocable family trusts.
Background
Relay Therapeutics, Inc. operates within the biological products sector, focusing on innovative therapeutic solutions. The company is incorporated in Delaware and has its business address in Cambridge, Massachusetts. Its stock is traded under the ticker symbol RLAY.
What the Filing Says
The SEC filing, accession number 0001193125-26-418096, details the sale of shares by Patel, indicating a structured approach to stock transactions through a Rule 10b5-1 trading plan established on October 30, 2025. The filing states, "The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025." This plan allows executives to sell shares without the appearance of insider trading.
Impact
This transaction may affect investor sentiment regarding Relay Therapeutics and its leadership. As a key executive, Patel's stock sales can signal confidence or concern about the company's future performance. The biotechnology industry is closely watched for such executive actions, as they can influence market perceptions and investor decisions.
What's Next
The filing does not say what happens next.